---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-24-000053"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:47:37.102699+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end

## Summary
- Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.
- R&D expenses increased to $32.6M (vs $17.4M) driven by IBD pipeline advancement; no acquired IPR&D in Q2 2024.
- SPY001 (anti-α4β7) Phase 1 dosing initiated; interim proof-of-concept data expected by end of 2024 for every-8-12 week dosing.
- SPY002 (anti-TL1A) two candidates with subnanomolar potency; FIH trials in H2 2024 with interim data in H1 2025.
- SPY003 (anti-IL-23) development candidate nominated; FIH trial expected in H1 2025; $426M cash runway into 2027.

## SEC filing metadata
- accession: 0001636282-24-000053
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000053/0001636282-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628224000053/syre-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-24-000053
- JSON: https://secwatch.observer/filing/0001636282-24-000053.json
- Plain text: https://secwatch.observer/filing/0001636282-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.